Chemaphor Inc.

Chemaphor Inc.

August 12, 2009 09:00 ET

Chemaphor Announces Formation of Expert Business and Technology Advisory Team

OTTAWA, ONTARIO--(Marketwire - Aug. 12, 2009) - Chemaphor (TSX VENTURE:CFR) is proud to announce the formation of a Business and Technology Advisory Team to help provide an expert third party perspective in the strategic areas which Chemaphor is pursuing.

The 5-member Advisory Team is chaired by Mr. John Oliver. As a former VP of Eli Lilly, as well as President of Dow Agrosciences Canada, and now President of Maple Leaf Bio Concepts, John's leadership in the agriculture, animal health and pharmaceutical arenas is widely recognized. In terms of the Chemaphor Advisory Team Mr. Oliver comments "we have assembled a team with deep business and scientific expertise, which will help us develop a sound roadmap for the future."

Dr. Paul Dick, CEO of Chemaphor, concludes, "Chemaphor will draw upon the collective expertise and experiences of this team in conducting our current product development activities as we look to further grow into a natural product development and wellness company."

The other members of the Advisory Team are:

Murray McLaughlin Ph.D., has held a variety of positions in agriculture-related areas over the last thirty years: Green Giant; Elanco; President of Ag-West Biotech in Saskatoon, where he helped establish a world leading ag-biotech center; Deputy Minister, Saskatchewan Agriculture and Food, and President of Ontario Agri-Food Technologies. In 1999 he became President and CEO of Foragen Technologies Management Inc., a company involved in agricultural technology and company creation. In 2005 he founded a consulting business, McLaughlin Consultants, and has worked with several major clients. He was Director Business Development for Canadian Light Source for three years and presently is President of the Sustainable Chemistry Alliance.

Mr. Richard Smith is presently Chairman of the Board of SemBioSys Genetics Inc. (TSX:SBS); co-chair of BioAlberta; and serves as a Director on the boards of Commercial Solutions Inc. (TSX:CSA); AVAC, and AgStream Inc. Mr. Smith has significant senior management experience in the life sciences area, including human pharmaceuticals, animal health and plant sciences with Eli Lilly and Company, as well as involvement in several commercialization initiatives in plant biotechnology. From 1997 to 2005 he was President and CEO of Dow AgroSciences Canada Inc., a wholly owned subsidiary of the Dow Chemical Company.

John Brennan Ph.D., is Vice President of Research and Development for Nutreco Canada Inc., where he has been responsible for Research and Development and Technology Application for the past 8 years. He holds a PhD in animal nutrition from the University of Alberta and began his career as a Research Scientist. Prior to his current position, John established and led a clinical research facility, Agresearch, serving the needs of international animal health and nutrition companies. John is based in Guelph Ontario.

Mr. Jolyon Burton is co-founder, CEO and Head of Investment Banking of Bloom Burton & Co. Previously Mr. Burton spent six years at Dundee Securities' Healthcare & Biotechnology Investment Banking Group. He has been involved in numerous public financings on all exchanges and numerous cross-border deals, helping the Dundee team grow into a North American biotechnology financing and M&A specialist, completing financings for private companies, engineering several M&A transactions, completing IPOs, CPCs and international financings.

Joseph A. Dunn, Ph.D., is CEO of OmniPharm Research International Inc., and President of the Snyder Seed Corporation, both of Buffalo, New York. At OmniPharm Dr. Dunn manages three drug discovery and development programs in the areas of infectious diseases, chronic inflammation, and cancer. Dr. Dunn has held positions as a Principal Scientist at Sterling Winthrop Pharmaceuticals, as a Senior Scientist at the Eastman Kodak Company, and a Senior Research Pharmacologist at the Colgate Palmolive Company. He has been the Principal Investigator for twenty-five pharmaceutical and agricultural product development grants awarded primarily by the NIH and USDA Small Business Innovative Research grant programs. From September 2008 to January 2009, Dr. Dunn served as the Deputy Under Secretary for USDA's Research, Education and Economics (REE) mission area after serving as Special Advisor to the REE Under Secretary and as the mission area's principal liaison for bioenergy, bioproducts, specialty crops and nanotechnology research, education and extension.

About Chemaphor

Chemaphor Inc. ( uses its core expertise in chemistry to develop premium products for the animal health, skin care cosmetics, pharmaceutical and specialty chemical markets. Chemaphor's goal is to fully exploit its proprietary platform of carotenoid oxidation compounds by finding recognized partners to commercialize its products in multiple, large markets.

Forward Looking Statements

This press release contains forward-looking statements regarding, among other things, Chemaphor's beliefs, plans, objectives, strategies, estimates, intentions and expectations. Actual results and events may differ materially from those included in, contemplated or implied by such forward looking statements for a variety of reasons. When used in this press release, the words "seek", "believe", "develop", "intends", "will", "may", "potential", "should" and similar expressions are intended to be among the statements that identify forward-looking statements. Forward-looking statements are subject to inherent risks and uncertainties including, but not limited to, market and general economic conditions, the availability to attract and retain key personnel, the availability and terms of financing, the scientific and commercial viability of planned products, changes in Chemaphor's relationship with its key suppliers and partners, competitive factors, changes in regulatory environments affecting Chemaphor's business, and the accuracy in management's assumptions. This list is not exhaustive of the factors that may affect any of Chemaphor's forward-looking statements. Investors and others should carefully consider these and other factors and not place undue reliance on these forward-looking statements. In addition, these forward-looking statements relate to the date on which they were made and Chemaphor disclaims and has no intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information